Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
US Army
Dow
QuintilesIMS
Healthtrust
Teva
McKinsey
Harvard Business School
Deloitte

Generated: August 21, 2017

DrugPatentWatch Database Preview

Drospirenone; ethinyl estradiol; levomefolate calcium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for drospirenone; ethinyl estradiol; levomefolate calcium and what is the scope of drospirenone; ethinyl estradiol; levomefolate calcium patent protection?

Drospirenone; ethinyl estradiol; levomefolate calcium
is the generic ingredient in three branded drugs marketed by Bayer Hlthcare and Watson Labs Inc, and is included in four NDAs. There are four patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Drospirenone; ethinyl estradiol; levomefolate calcium has ninety-seven patent family members in thirty-nine countries.

There are ten drug master file entries for drospirenone; ethinyl estradiol; levomefolate calcium. Three suppliers are listed for this compound.

Summary for Generic Name: drospirenone; ethinyl estradiol; levomefolate calcium

Tradenames:3
Patents:4
Applicants:2
NDAs:4
Drug Master File Entries: see list10
Suppliers / Packagers: see list3
Clinical Trials: see list2,449
Drug Prices:see low prices
DailyMed Link:drospirenone; ethinyl estradiol; levomefolate calcium at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
SAFYRAL
drospirenone; ethinyl estradiol; levomefolate calcium
TABLET;ORAL022574-001Dec 16, 2010ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Bayer Hlthcare
SAFYRAL
drospirenone; ethinyl estradiol; levomefolate calcium
TABLET;ORAL022574-001Dec 16, 2010ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Bayer Hlthcare
BEYAZ
drospirenone; ethinyl estradiol; levomefolate calcium
TABLET;ORAL022532-001Sep 24, 2010ABRXNoNo► Subscribe► SubscribeY ► Subscribe
Bayer Hlthcare
SAFYRAL
drospirenone; ethinyl estradiol; levomefolate calcium
TABLET;ORAL022574-001Dec 16, 2010ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Bayer Hlthcare
BEYAZ
drospirenone; ethinyl estradiol; levomefolate calcium
TABLET;ORAL022532-001Sep 24, 2010ABRXNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: drospirenone; ethinyl estradiol; levomefolate calcium

Non-Orange Book Patents for Generic Ingredient: drospirenone; ethinyl estradiol; levomefolate calcium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,569,557Compositions of estrogen-cyclodextrin complexes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: drospirenone; ethinyl estradiol; levomefolate calcium

Country Document Number Estimated Expiration
Argentina032205► Subscribe
Portugal1044975► Subscribe
Germany50015815► Subscribe
Japan2013047279► Subscribe
European Patent Office1695975► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/032United Kingdom► SubscribePRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
C0022France► SubscribePRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Federal Trade Commission
Chubb
Moodys
AstraZeneca
Cerilliant
Fuji
US Army
Daiichi Sankyo
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot